{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:56:06Z","timestamp":1783436166937,"version":"3.54.6"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.amjcard.2024.10.038","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:48:53Z","timestamp":1732088933000},"page":"17-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis"],"prefix":"10.1016","volume":"237","author":[{"given":"Meghna","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal Murali","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3988-6211","authenticated-orcid":false,"given":"Chidubem","family":"Ezenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ismayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Nanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Goldsweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.10.038_bib0001","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey","volume":"42","author":"Cao","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0002","first-page":"340","article-title":"P2Y12 inhibitor monotherapy after percutaneous coronary intervention","volume":"9","author":"Zhou","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0003","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","article-title":"Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease","volume":"9","author":"Valgimigli","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/ehjcvp\/pvad016","volume":"9","author":"Navarese","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0007","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0008","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0009","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0877","article-title":"P2Y12 inhibitor monotherapy vs dual antiplatelet therapy after deployment of a drug-eluting stent: the SHARE randomized clinical trial","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0011","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0012","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, ed. Cochrane Handbook for Systematic Reviews of Interventions Version 6.4. Cochrane; updated August 2023:2023.\u201d Available at: https:\/\/training.cochrane.org\/handbook\/archive\/v6.3 Accessed on July 6, 2024."},{"key":"10.1016\/j.amjcard.2024.10.038_bib0013","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0014","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0016","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.4244\/EIJ-D-19-00202","article-title":"Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial","volume":"15","author":"Serruys","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial","volume":"10","author":"Vranckx","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0018","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamacardio.2019.3355","article-title":"Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial","volume":"4","author":"Tomaniak","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0019","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012004","article-title":"Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort","volume":"15","author":"Obayashi","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0021","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0022","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0023","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0024","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0026","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0027","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"142","author":"O'Donoghue","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0028","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jcin.2020.11.046","article-title":"Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: an individual patient-level meta-analysis","volume":"14","author":"Valgimigli","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0029","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt.2226","article-title":"Efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention: a meta-analysis","volume":"110","author":"Gelbenegger","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0032","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0033","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.4244\/EIJ-E-24-00009","article-title":"Antiplatelet monotherapy after DAPT: is clopidogrel the new standard? Pros and cons","volume":"20","author":"Kim","year":"2024","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0034","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin Receptor antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0035","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019432","article-title":"When less becomes more: insights on the pharmacodynamic effects of aspirin withdrawal in patients with potent platelet P2Y12 inhibition induced by ticagrelor","volume":"9","author":"Capodanno","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0037","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0038","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/eurheartj\/ehad876","article-title":"Aspirin-free antiplatelet strategies after percutaneous coronary interventions","volume":"45","author":"Capranzano","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0039","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0041","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0042","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0043","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0044","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0045","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0046","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0047","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.phrs.2014.12.003","article-title":"Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration","volume":"93","author":"Habib","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0048","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0049","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13216","article-title":"Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects","volume":"14","author":"Traby","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0051","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3895205","article-title":"Thrombotic vs. bleeding Events of Interruption of Dual antiplatelet Therapy within 12\u2009months among Patients with Stent-Driven High ischemic Risk Definition following PCI","volume":"2022","author":"Wang","year":"2022","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0052","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0053","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0054","unstructured":"ClinicalTrials.gov. Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05491200. Accessed on July 6, 2024."},{"key":"10.1016\/j.amjcard.2024.10.038_bib0055","first-page":"240","article-title":"A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial","volume":"19","author":"Tarantini","year":"2023","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0056","unstructured":"ClinicalTrials.gov. 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI (BULK-STEMI). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04570345. Accessed on July 6, 2024"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0057","unstructured":"ClinicalTrials.gov. Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention (MATE). Available at:https:\/\/clinicaltrials.gov\/show\/NCT04937699. Accessed on July 6, 2024."},{"key":"10.1016\/j.amjcard.2024.10.038_bib0058","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.4244\/EIJ-D-23-00125","article-title":"P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial","volume":"19","author":"Guimar\u00e3es","year":"2023","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0059","unstructured":"Clinicaltrials.gov. Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients (LEGACY). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05125276. Accessed on July 6, 2024."},{"key":"10.1016\/j.amjcard.2024.10.038_bib0060","unstructured":"Clinicaltrials.gov. SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3 (SMART-CHOICE3). Available at: https:\/\/clinicaltrials.gov\/show\/NCT04418479. Accessed on July 6, 2024."},{"key":"10.1016\/j.amjcard.2024.10.038_bib0061","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cpt.3209","article-title":"Ticagrelor versus adjusted-dose prasugrel in acute coronary syndrome with percutaneous coronary intervention","volume":"116","author":"Tsai","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0062","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/eurheartj\/ehz917","article-title":"Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study","volume":"41","author":"Schnorbus","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.10.038_bib0063","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924007987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924007987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T13:17:55Z","timestamp":1737551875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924007987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":63,"alternative-id":["S0002914924007987"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.10.038","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}